Magnesium Treatment on Vitamin D Metabolism in Participants Completed Personalized Prevention of Colorectal Cancer Trial

Last updated: August 22, 2024
Sponsor: Vanderbilt University Medical Center
Overall Status: Completed

Phase

N/A

Condition

Colorectal Cancer

Colon Cancer; Rectal Cancer

Colon Cancer

Treatment

Placebo

Magnesium glycinate

Clinical Study ID

NCT03265483
100106b
  • Ages 40-85
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

One striking observation is that a large portion of the inter-person variation in serum 25-hydroxyvitamin D (25(OH)D) levels is unexplained. In vitro and in vivo studies indicate vitamin D synthesizing and metabolizing enzymes are Mg-dependent. Magnesium (Mg) supplementation substantially reversed the resistance to vitamin D treatment in patients with magnesium-dependent vitamin-D-resistant rickets. The investigators reported in 2013 from observational studies conducted in the general US population that Mg intake significantly interacted with vitamin D intake in affecting vitamin D status as well as interacted with serum 25(OH)D in risk of cardiovascular disease mortality and, maybe, colorectal cancer mortality. The potential interaction between Mg and vitamin D was supported by two subsequent studies, including a Finnish cohort study and a mouse study.

In the parent study (Personalized Prevention of Colorectal Cancer Trial, NCT01105169), the investigators proposed to measure blood concentration of total 25(OH)D as a secondary aim using Elisa approach. However, following the novel finding of Mg-vitamin D interaction published by the investigators in 2013, they submitted a separate grant application to NCI which was funded in 2014. In the new study, the investigators proposed to use a LC-MS approach, which is more accurate and specific than an Elisa method, to measure 5 vitamin D metabolites. This new ancillary study allows the investigators to evaluate whether Mg supplementation differentially affects vitamin D synthesis and metabolism dependent on baseline serum 25(OH)D levels using existing biospecimens collected in our double-blind placebo-controlled randomized chemoprevention trial.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Participants from our parent study (Personalized Prevention of Colorectal CancerTrial, NCT#01105169, IRB#100106);

  2. Participants who had completed the above study before the time of the sampleselection (October 2015);

  3. Participants consent to store/share samples for future research in colorectaltumors.

Exclusion

Exclusion Criteria:

  1. Participants cannot provide their blood samples in the parent study.

Study Design

Total Participants: 180
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
September 01, 2014
Estimated Completion Date:
August 31, 2016

Connect with a study center

  • Vanderbilt University Medical Center

    Nashville, Tennessee 37203
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.